Thousands of pancreatic cancer patients tracked in new drug study

NCT ID NCT06375473

Recruiting now Knowledge-focused Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 3,000 pancreatic cancer patients in China who are receiving irinotecan liposome II as part of their treatment. Researchers will collect data on side effects, survival, and how well the drug controls the cancer. The goal is to understand how this treatment works in real-world settings, outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: irinotecan liposome II
What this could lead to: If successful, this study could provide clearer evidence on how well irinotecan liposome II works for pancreatic cancer in everyday medical practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient differences. It does not test a new treatment but gathers data on existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Anhui Provincial Cancer Hospital
RECRUITING

Hefei, Anhui, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China
Henan Provincial People's Hospital
RECRUITING

Henan, China
Ningbo Medical Center Lihuili Hospital
RECRUITING

Ningbo, China
Peking Unicersity First Hospital
RECRUITING

Beijing, China
Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China
Renji，Hospital
RECRUITING

Shanghai, China
The First Affiliated Hospital of Guangxi Medical University
RECRUITING

Nanning, Guangxi, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China
Wuhan Union Hospital of China
RECRUITING

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.